Online citations, reference lists, and bibliographies.

Cytoreductive Surgery And Perioperative Intraperitoneal Chemotherapy In Recurrent Ovarian Cancer.

A. Tentes, O. Korakianitis, S. Kakolyris, D. Kyziridis, D. Veliovits, C. Karagiozoglou, E. Sgouridou, K. Moustakas
Published 2010 · Medicine

Cite This
Download PDF
Analyze on Scholarcy
Share
BACKGROUND AND AIMS Cytoreductive surgery with perioperative intraperitoneal chemotherapy is another approach for recurrent ovarian cancer. The purpose of the study was to assess the feasibility and the effect of cytoreduction and perioperative intraperitoneal chemotherapy in recurrent ovarian cancer. PATIENTS AND METHODS Twenty-nine women with recurrent ovarian cancer underwent cytoreductive surgery. Clinical variables were correlated to morbidity, hospital mortality, recurrences, and survival. RESULTS Complete cytoreduction was possible in 58.6%. Extensive seeding of the small bowel and distant metastases excluded the possibility of performing complete cytoreduction. Perioperative intraperitoneal chemotherapy was given in 75.9%. Morbidity and hospital mortality rates were subsequently 24.1% and 3.4%. Recurrence was recorded in 48.3%. The extent of peritoneal dissemination was an independent variable of recurrence (P= 0.014). The 5-year survival rate was 30%. The extent of peritoneal dissemination and the completeness of cytoreduction were related to survival (P <0.05). The completeness of cytoreduction independently influenced survival (P= 0.013). CONCLUSIONS Secondary cytoreduction with intraperitoneal chemotherapy is feasible in most women with recurrent ovarian cancer with acceptable morbidity and mortality. Complete cytoreduction is not possible if distant and unresectable metastases are present or if the small bowel is extensively seeded. Long-term survivors are patients with limited peritoneal dissemination who may undergo complete cytoreduction.
This paper references
10.1016/S0039-6109(05)70171-7
Cytoreductive surgery for ovarian cancer.
T. Randall (2001)
10.1016/j.ygyno.2009.04.026
Topotecan versus treosulfan, an alkylating agent, in patients with epithelial ovarian cancer and relapse within 12 months following 1st-line platinum/paclitaxel chemotherapy. A prospectively randomized phase III trial by the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group (A
W. Meier (2009)
10.1016/S0748-7983(03)00149-5
Pseudomyxoma peritonei: a review of 62 cases.
S. van Ruth (2003)
10.1053/EJSO.2000.1007
Impact of secondary cytoreductive surgery on survival of patients with advanced epithelial ovarian cancer.
R. Zang (2000)
10.1007/978-1-4613-1245-1_7
Pathobiology of peritoneal carcinomatosis from ovarian malignancy.
T. A. Sugarbaker (1996)
The effect of antineoplastic agents on wound healing.
Ferguson Mk (1982)
10.1016/s1055-3207(03)00048-6
Peritonectomy procedures.
P. Sugarbaker (1996)
AGO Ovarian Committee, AGO Ovarian Study Group (AGO-OVAR): The role of surgery in recurrent ovarian cancer
J Pfisterer (2005)
Advances in the management of epithelial ovarian cancer.
S. Memarzadeh (2001)
10.1007/s004230050246
Management of peritoneal-surface malignancy: the surgeon’s role
P. Sugarbaker (1999)
10.1007/s10434-999-0727-7
Results of Treatment of 385 Patients With Peritoneal Surface Spread of Appendiceal Malignancy
P. Sugarbaker (1999)
10.1002/1098-2388(200007/08)19:1<62::AID-SSU10>3.0.CO;2-O
Recurrent ovarian carcinoma: is there a place for surgery?
L. Chen (2000)
10.1007/978-1-4613-1245-1_6
Surgically directed chemotherapy: heated intraperitoneal lavage with mitomycin C.
V. Fernandez-Trigo (1996)
Ovarian cancer: Rethinking Prognostic Factors and Chemotherapy
J Neijt (1994)
Secondary cytoreductive surgery in ovarian cancer.
G. Michel (1989)
fect of cytoreductive surgery on survival of patients with recurrent epithelial ovarian cancer
RY Zang (2004)
10.1136/IJGC-00009577-200303001-00132
SECONDARY CYTOREDUCTIVE SURGERY FOR RECURRENT OVARIAN CANCER
P. Harter (2003)
10.1097/00000658-199809000-00007
Prospective randomized trial of early postoperative intraperitoneal chemotherapy as an adjuvant to resectable gastric cancer.
W. Yu (1998)
10.1177/030089160108700302
Cytoreductive Surgery Followed by Intraperitoneal Hyperthermic Perfusion in the Treatment of Recurrent Epithelial Ovarian Cancer: A Phase II Clinical Study
M. Deraco (2001)
10.1002/cncr.23553
Cytoreductive surgery (peritonectomy procedures) combined with hyperthermic intraperitoneal chemotherapy (HIPEC) in the treatment of diffuse peritoneal carcinomatosis from ovarian cancer
A. di Giorgio (2008)
10.1053/EJSO.2002.1380
Peritoneal cancer index: a prognostic indicator of survival in advanced ovarian cancer.
A. Tentes (2003)
10.1111/J.1525-1438.2006.00580.X
Long‐term survival in advanced ovarian carcinoma following cytoreductive surgery with standard peritonectomy procedures
A. Tentes (2006)
10.1002/1096-9098(200009)75:1<24::AID-JSO5>3.0.CO;2-L
Effect of cytoreductive surgery on survival of patients with recurrent epithelial ovarian cancer.
R. Zang (2000)
10.1111/J.1525-1438.2003.13319.X
Long‐term results of cytoreductive surgery for advanced and recurrent epithelial ovarian cancers and papillary serous carcinoma of the peritoneum
M. Look (2003)
10.1200/JCO.20.5.1248
Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis.
R. Bristow (2002)
10.1006/GYNO.2001.6404
Secondary cytoreductive surgery for patients with recurrent epithelial ovarian carcinoma.
C. Scarabelli (2001)
Surgery for recurrent ovarian cancer.
P. Rose (2000)
10.1002/1097-0142(19951101)76:9<1606::AID-CNCR2820760917>3.0.CO;2-H
Secondary cytoreductive surgery for recurrent ovarian cancer. A prospective study
S. Eisenkop (1995)
10.1002/(SICI)1097-0142(20000101)88:1<144::AID-CNCR20>3.0.CO;2-X
The role of secondary cytoreductive surgery in the treatment of patients with recurrent epithelial ovarian carcinoma
S. Eisenkop (2000)
10.1097/00006534-198212000-00098
The effect of antineoplastic agents on wound healing.
M. Ferguson (1982)
Results of treatment of 358 patients with peritoneal surface spread of appendiceal malig
P Sugarbaker (1996)
Pathophysiology of peritoneal carcinomatosis from ovarian malignancy. In: Sugarbaker PH (ed) Peritoneal Carcinomatosis: Drugs and Diseases, Norwell, MA
TA Sugarbaker (1996)
Advances in themanagement of epithelial ovarian cancer
S Memarzadeh (2001)
toreductive surgery followed by intraperitoneal hyperthermic perfusion in the treatment of recurrent epithelial ovarian cancer : a phase II clinical study
M Deraco (2001)
10.1053/EJSO.2001.1152
Cytoreduction and intraperitoneal chemotherapy for the management of peritoneal carcinomatosis, sarcomatosis and mesothelioma.
G. Begossi (2002)
10.1186/1477-7819-2-21
Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in peritoneal carcinomatosis from ovarian cancer
P. Piso (2004)
10.1200/JCO.2003.04.187
Randomized trial of cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy and palliative surgery in patients with peritoneal carcinomatosis of colorectal cancer.
V. Verwaal (2003)
10.1111/J.1525-1438.2005.00430.X
The role of surgery in recurrent ovarian cancer
J. Pfisterer (2005)
10.1111/IGC.0b013e3181a1c7aa
Epithelial Ovarian Cancer: Role of Pegylated Liposomal Doxorubicin in Prolonging the Platinum-Free Interval and Cancer Antigen 125 Trends During Treatment
J. Tanguay (2009)
10.1016/S1055-3207(03)00047-4
Management of peritoneal surface malignancy
P. Sugarbaker (2003)
10.1016/0020-7292(90)90934-D
Secondary cytoreductive surgery for recurrent epithelial ovarian cancer
M. Morris (1990)



This paper is referenced by
Semantic Scholar Logo Some data provided by SemanticScholar